Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs By: Foghorn Therapeutics, Inc. via GlobeNewswire October 24, 2023 at 08:00 AM EDT CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland. 6th Annual Targeted Protein Degradation Summit Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented. Danette Daniels, Foghorn’s Vice President, Protein Degradation Platform, will provide the conference’s opening remarks as the Chair. Presentation Details Title: Advancement of Degraders Targeting Key Chromatin Regulators Involved in Disease/OncologyPresenter: Steve Bellon, Chief Scientific Officer, Foghorn Therapeutics Session: Keynote Plenary SessionDate: October 31, 2023Time: 9:30 a.m. ETTitle: Lay of the Land – What Does the Next 3 Years of TPD Drug Discovery & Development Look Like?Presenter: Laura La Bonte, Senior Director, Biology & Research Portfolio Strategy, Foghorn TherapeuticsSession: Clinical DevelopmentDate: October 31, 2023Time: 2:30 p.m. ET Connective Tissue Oncology Society Annual Meeting Presentation Details Title: Preliminary results from a Phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumorsPresenter: J. Andrew Livington, M.D., M.S., MD Anderson Cancer CenterSession: Session 4, Paper 25Session date and time: November 2, 2023, 16:00-17:30 WETTitle: Pharmacodynamic and mechanistic impacts of FHD-609, A BRD9 degrader, in a Phase 1 study in patients with advanced synovial sarcoma or SMARCB1-loss tumorsSession date and time: November 2, 2023, 17:30-18:30 WETPresenter: Mike Collins, Senior Scientist, Foghorn Therapeutics About Foghorn Therapeutics Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn. Forward-Looking StatementsThis press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Contacts:Greg Dearborn, Foghorn Therapeutics Inc. (Investors)gdearborn@foghorntx.com Karin Hellsvik, Foghorn Therapeutics Inc. (Media)khellsvik@foghorntx.com Michael Lampe, ScientPR (Media)michael@scientpr.com Hans Vitzthum, LifeSci Advisors (Investors)hans@lifesciadvisors.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs By: Foghorn Therapeutics, Inc. via GlobeNewswire October 24, 2023 at 08:00 AM EDT CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland. 6th Annual Targeted Protein Degradation Summit Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented. Danette Daniels, Foghorn’s Vice President, Protein Degradation Platform, will provide the conference’s opening remarks as the Chair. Presentation Details Title: Advancement of Degraders Targeting Key Chromatin Regulators Involved in Disease/OncologyPresenter: Steve Bellon, Chief Scientific Officer, Foghorn Therapeutics Session: Keynote Plenary SessionDate: October 31, 2023Time: 9:30 a.m. ETTitle: Lay of the Land – What Does the Next 3 Years of TPD Drug Discovery & Development Look Like?Presenter: Laura La Bonte, Senior Director, Biology & Research Portfolio Strategy, Foghorn TherapeuticsSession: Clinical DevelopmentDate: October 31, 2023Time: 2:30 p.m. ET Connective Tissue Oncology Society Annual Meeting Presentation Details Title: Preliminary results from a Phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumorsPresenter: J. Andrew Livington, M.D., M.S., MD Anderson Cancer CenterSession: Session 4, Paper 25Session date and time: November 2, 2023, 16:00-17:30 WETTitle: Pharmacodynamic and mechanistic impacts of FHD-609, A BRD9 degrader, in a Phase 1 study in patients with advanced synovial sarcoma or SMARCB1-loss tumorsSession date and time: November 2, 2023, 17:30-18:30 WETPresenter: Mike Collins, Senior Scientist, Foghorn Therapeutics About Foghorn Therapeutics Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn. Forward-Looking StatementsThis press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Contacts:Greg Dearborn, Foghorn Therapeutics Inc. (Investors)gdearborn@foghorntx.com Karin Hellsvik, Foghorn Therapeutics Inc. (Media)khellsvik@foghorntx.com Michael Lampe, ScientPR (Media)michael@scientpr.com Hans Vitzthum, LifeSci Advisors (Investors)hans@lifesciadvisors.com
CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland. 6th Annual Targeted Protein Degradation Summit Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented. Danette Daniels, Foghorn’s Vice President, Protein Degradation Platform, will provide the conference’s opening remarks as the Chair. Presentation Details Title: Advancement of Degraders Targeting Key Chromatin Regulators Involved in Disease/OncologyPresenter: Steve Bellon, Chief Scientific Officer, Foghorn Therapeutics Session: Keynote Plenary SessionDate: October 31, 2023Time: 9:30 a.m. ETTitle: Lay of the Land – What Does the Next 3 Years of TPD Drug Discovery & Development Look Like?Presenter: Laura La Bonte, Senior Director, Biology & Research Portfolio Strategy, Foghorn TherapeuticsSession: Clinical DevelopmentDate: October 31, 2023Time: 2:30 p.m. ET Connective Tissue Oncology Society Annual Meeting Presentation Details Title: Preliminary results from a Phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumorsPresenter: J. Andrew Livington, M.D., M.S., MD Anderson Cancer CenterSession: Session 4, Paper 25Session date and time: November 2, 2023, 16:00-17:30 WETTitle: Pharmacodynamic and mechanistic impacts of FHD-609, A BRD9 degrader, in a Phase 1 study in patients with advanced synovial sarcoma or SMARCB1-loss tumorsSession date and time: November 2, 2023, 17:30-18:30 WETPresenter: Mike Collins, Senior Scientist, Foghorn Therapeutics About Foghorn Therapeutics Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn. Forward-Looking StatementsThis press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Contacts:Greg Dearborn, Foghorn Therapeutics Inc. (Investors)gdearborn@foghorntx.com Karin Hellsvik, Foghorn Therapeutics Inc. (Media)khellsvik@foghorntx.com Michael Lampe, ScientPR (Media)michael@scientpr.com Hans Vitzthum, LifeSci Advisors (Investors)hans@lifesciadvisors.com